Status:
UNKNOWN
Cardiovascular Manifestations of COVID-19
Lead Sponsor:
Memorial Hermann Health System
Conditions:
Cardiovascular Diseases
COVID
Eligibility:
All Genders
18+ years
Brief Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for the novel coronavirus disease 2019 (COVID-19). The first reports of COVID-19 came from Wuhan, China in Dece...
Detailed Description
Significance: Coronavirus disease 2019 (COVID-19) is a rapidly spreading infection that has already affected close to a million patients around the world. It is estimated that COVID-19 will be lethal...
Eligibility Criteria
Inclusion
- Patients admitted to the hospital with symptoms of fever, sore throat, cough, nasal congestion and/or dyspnea who were tested positive for SARS-CoV-2 by PCR
Exclusion
- Patients of high clinical suspicion for COVID-19 with only one negative PRC test for SARS-CoV-2
- Patients with COVID-19 who do not require hospitalization
Key Trial Info
Start Date :
March 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT04335630
Start Date
March 30 2020
End Date
March 1 2022
Last Update
April 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Hermann Hospital-Texas Medical Center
Houston, Texas, United States, 77030